Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Glympse Bio is raising $46,699,979.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Caroline Loew played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Glympse Bio
We are pioneering the development of synthetic biomarkers biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence that are bioengineered to be perfectly tunable to any disease, absolutely specific, and offer earlier measures of response to disease and treatment. Our synthetic biomarkers are administered to patients and tailor-made to query the activity of key biological targets such as proteases a class of enzymes that drive critical disease pathways. Synthetic biomarkers exploit the human bodys own proteases and in vivo trafficking to create perfectly refined and trackable markers of disease which are accurate, sensitive, specific and detectable in a simple noninvasive urine test. Its the new frontier of liquid biopsy. Our lead indication is in NASH, and our second indication is in Oncology. Our development pipeline is broad, and we have preclinical validation in over 10 diseases.

To learn more about Glympse Bio, visit http://www.glympsebio.com/

Contact:
Caroline Loew, Chief Executive Officer
617-863-3636
https://www.linkedin.com/in/carolineloew/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved